Advertisement

Topics

Companies Related to "T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs" [Most Relevant Company Matches] RSS

08:34 EST 14th December 2018 | BioPortfolio

Here are the most relevant search results for "T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs" found in our extensive corporate database of over 50,000 company records.

Showing "Patients With Prior Drug Treatment Resistance Each Three" Companies 1–25 of 8,700+

Relevant

VIRalliance

VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology.VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment.PHENOSCRIPT™ is the first of these tests to be made available to the public. PHENOSCRIPT™ is a novel and rapid HIV phen...


Teva Pharmaceutical Industries Ltd. & OncoGenex Pharmaceuticals, Inc.

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the le...

Discuva

Discuva aims to revolutionise the treatment of disease caused by bacterial infection by discovering and developing new antibiotics against highly drug-resistant pathogens. The company’s innovative proprietary technologies both identify new small molecule drugs against novel bacterial targets and facilitate their progression through to drug candidates ...


Deciphera Pharmaceuticals, Inc.,

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

Mpex Pharmaceuticals, Inc.

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacte...

KIYATEC, Inc.

KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated...

Paratek Pharmaceuticals Incorporated

Paratek's mission is to overcome the major worldwide problem of bacterial resistance through the application of new proprietary technology and through the development of new antibiotics. Paratek has established two product development programs to identify and develop new pharmaceuticals for the treatment of infectious diseases:The Tetracycline Resistance Project ("Tet Project") based on expertise ...

Hobson Prior

Hobson Prior was established by a team of highly experienced recruitment professionals to address a gap in the market for the provision of a specialised contingent recruitment service. Focused solely within the pharmaceutical, biotechnology, life sciences and medical devices industries Hobson Prior operates on a Pan-European basis.Hobson Prior employs a comprehensive operating approach combining t...

Glactone Pharma AB

Glactone Pharma AB is developing a drug for the treatment of castration resistant prostate cancer. Research has shown that the natural product galiellalactone can modulate a signaling protein (STAT3) that is over activated in cancer cells. The goal is to develop drugs against metastasizing cancer where galiellalactone is used as a chemical starting point to make new novel, patentable compounds. ...

Allecra Therapeutics GmbH

Allecra Therapeutics Allecra is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra’s Mission Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving ...

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, ...

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...

Notable Labs

Notable Labs’ mission is to change the way cancer is treated, which starts with putting patients first. The company is developing a personalized treatment service for people with cancer that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor. Focusing on individual patients and existing treatments, the c...

BioAlliance Pharma

BioAlliance Pharma (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections.To attack the challenge of resistance, the company has multiple product opportunities in two broad proprietary drug delivery systems represented by the Lauriad® adhesive tech...

Signature Bioscience Incorporated

Signature is a detection-based drug discovery company committed to efficiently delivering highly-qualified pre-clinical leads for potential treatment of cancer, inflammation and other diseases. Incorporating several proprietary and revolutionary technologies and aided by the skills of its world-class team, Signature has created WaveScreen™, a novel drug discovery platform that integrates biology...

ConjuGon

The rise of drug-resistant strains of pathogenic bacteria is quickly becoming a health problem of potentially crisis proportions. Virtually all experts agree that entirely new approaches are needed to go beyond the use of traditional antibiotics. Fundamentally new, even radical, anti-microbial agents are necessary to kill pathogenic bacteria while minimizing the ability of the bacteria to develop ...

Amerimmune Pharmaceuticals Incorporated

Amerimmune is engaged in pharmaceutical research and development with the primary purpose of developing Cytolin, a drug designed to protect the immune system, especially in patients suffering from human immunodeficiency virus (HIV). The company believes that Cytolin is an important drug for the growing number of patients who have not been receiving treatment, for those who are on multi-drug therap...

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

Virco Lab, Inc.

Virco BVBA is a world leader in the field of HIV resistance testing services for clinical practice and clinical studies, advancing research that correlates laboratory testing with clinical management, while offering a wide range of HIV resistance diagnostics. (Virco Lab, Inc. is the US operating division of Virco.) The company applies the latest technologies in molecular biology, medical virology,...

Rational Therapeutics, Inc

Who are we?Rational Therapeutics, Inc. (RTI) is a free-standing research laboratory located in Long Beach, CA. Founded in 1993 by Dr. Robert Nagourney, a prominent hematologist/oncologist, Rational Therapeutics pioneers intelligent cancer therapies that are scientifically tailored for each individual patient. What do we do?Rational Therapeutics develops and provides cancer therapy recommendations,...

Gloucester Pharmaceuticals

Gloucester Pharmaceuticals acquires clinical-stage oncology drug candidates and advances them through regulatory approval and commercialization. The Company’s first candidate, ISTODAX® (romidepsin), a novel histone deacetylase (HDAC) inhibitor, is FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at le...

NewBiotics

NewBiotics Inc. is a pharmaceutical developer of breakthrough drugs to treat cancer and infectious disease. The privately held company is applying its Enzyme Catalyzed Therapeutic Activation (ECTA) technology to develop a new generation of pharmaceuticals that transform drug resis-tance into therapeutic advantage. Unlike conventional agents that kill diseased cells by enzyme inhibition – with to...

UTILITY therapeutics Limited

UTILITY therapeutics is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development...

UTILITY therapeutics Ltd

UTILITY is focused on developing and commercialising antibiotics in the US, to address the significant threat faced by healthcare systems and patients from multi-drug resistant bacterial infections. The World Health Organisation has stated that antibiotic resistance is one of the biggest threats to global health, food security, and development today.


More From BioPortfolio on "T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks